TAPUR Study Evaluating FDA-Approved Targeted Therapies for Advanced Cancers with Specific Tumor Gene Changes
Led by American Society of Clinical Oncology · Updated on 2026-09-22
4200
Participants Needed
181
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of FDA-approved targeted therapies for patients with advanced cancer whose tumors have specific genomic changes that may respond to these drugs. This non-randomized Phase 2 trial aims to understand the safety and effects of these targeted anticancer treatments in real-world clinical practice. The study catalogs molecular profiling tests used by doctors and helps develop ideas for further clinical trials.
Participants receive one of several targeted drug treatments based on their tumors genetic profile. These include drugs such as sunitinib, trastuzumab with pertuzumab, vemurafenib with cobimetinib, olaparib, nivolumab with ipilimumab, abemaciclib, talazoparib, atezolizumab with talazoparib, tucatinib with trastuzumab, futibatinib, dabrafenib with trametinib, or fam-trastuzumab deruxtecan-nxki. Dosage, frequency, and duration follow approved labeling. Each drug is matched to specific genomic variants identified in the tumor.
Participants must be at least 12 years old and have advanced cancer that is no longer benefiting from standard treatment or for which no approved therapy is available. They undergo genomic testing to identify actionable tumor variants and receive treatment accordingly. Researchers assess tumor response at 16 weeks and monitor overall survival for up to 3 years. Safety and treatment effects are observed throughout the study, which lasts until 2028, with results shared publicly as they become available.
CONDITIONS
Brief Title
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Research Team
L
Laurie Smith, MA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Precision off‑label targeted drug (TAPUR)
Standard care (contextual comparator)
What it is
An FDA‑approved targeted cancer drug repurposed for off‑label use based on a patient’s tumor genomic alteration within a single‑arm basket trial
Standard care consists of authorized treatments for each cancer type and genomic marker based on current guidelines
Role in trial
Investigational arm where therapy is assigned per tumor genomics
Not part of the trial, added for clinical context
Primary purpose
To assess safety and anti‑tumor activity of off‑label targeted drugs matched to tumor genomic alterations
To manage advanced cancers according to approved indications and guideline‑recommended biomarker‑based treatments
How it is given or performed
Selected targeted drug is administered as defined by the TAPUR protocol for each genomic cohort
Administered as per approved regimen for the patient’s specific cancer and biomarker
Evidence status
Emerging evidence from ongoing TAPUR cohorts evaluating response rates and survival signals in off‑label settings
Established efficacy supported by randomized trials and guideline recommendations in biomarker‑matched cancers
Important risks
Safety depends on each off‑label drug’s known risk profile; adverse events may vary in the new tumor context
Known risk profiles based on clinical trials in approved indications
Important limitations
Single‑arm design lacks control group; activity signals are hypothesis‑generating only
Not tested within this trial; indirect comparison only
Patient impact
May offer access to targeted treatment when standard options are exhausted, but patient benefit remains exploratory
Provides evidence‑based, guideline‑recommended treatment expected to benefit eligible patients
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 12Years +
All Genders
Eligibility Criteria
You may qualify if you...
12 years of age or older (some therapies not available for patients under 18)
Histologically confirmed advanced or metastatic solid tumor, multiple myeloma, or B cell non-Hodgkin lymphoma
No longer benefiting from standard cancer treatments or no standard treatment available as judged by treating physician
Performance status 0-2 according to ECOG criteria
Acceptable organ function including neutrophils ≥1500/µl, hemoglobin ≥9.0 g/dl, platelets ≥75,000/µl, bilirubin <2.0 mg/dl (except Gilbert's Syndrome), liver enzymes <2.5x ULN (or <5x ULN with liver metastases), creatinine ≤1.5x ULN or creatinine clearance ≥50 mL/min/1.73 m2
Measurable disease by physical exam, lab, or imaging per RECIST v1.1, Lugano criteria, or International Myeloma Working Group
Tumor genomic or protein expression test performed in accredited laboratory
Ability to understand and sign informed consent
Tumor genomic profile matches a single-agent FDA-approved targeted drug in the study
Able to swallow oral medications, no malabsorption syndrome
Agree to use contraception during and for 4 months after study for men and women of childbearing potential
You will not qualify if you...
Disease not measurable or assessable by imaging or physical exam (e.g., only elevated tumor markers)
Primary brain tumors or new untreated or progressive leptomeningeal metastases
Unstable brain metastases or leptomeningeal disease with recent seizures or neurological changes within 1 month
Clinically unstable brain metastases or on steroid treatment within 1 month prior to enrollment
Additional exclusion criteria may apply
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Varies by participant
Participants receive one of several FDA-approved targeted anticancer drugs selected based on their tumor's genetic profile. Treatment follows approved dosing schedules and continues as per label instructions.
Regular visits as per treatment protocol
Follow-up
Duration - Up to 3 years
Participants are monitored for tumor response and overall survival, with assessments conducted up to 3 years after starting treatment.
Periodic visits or contacts for survival and safety monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
12
Similar Trials
Evaluating 18F-Fluciclovine PETCT Imaging for Multiple Myeloma Detection and Monitoring
Evaluating 68Ga-BCMA PETCT Imaging for Detecting BCMA in Multiple Myeloma Patients in a Multicenter Study
Italian National Registry to Monitor Diagnosis and Treatment of Multiple Myeloma
A Physician and Patient-Powered Cohort Study
Evaluating BCMA-Targeted Prime CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma and Plasma Cell Disease
Phase 1 Study of Subcutaneous TQB2934 Injection for Treating Malignant Plasma Cell Tumors Including Multiple Myeloma
Phase Ib Study of Hemay181 Given by Intravenous Infusion for Patients Aged 18 to 75 With Advanced Solid Tumors Who Have Not Responded to Standard Treatments
Study of Allogeneic CD19 and BCMA CAR-T Cell Therapy for Adults with Relapsed or Refractory B-cell or Plasma Cell Tumors
Early Phase 1 Trial to Assess Safety and Effectiveness of RN1101 Treatment
Study of JS105 Combined With Various Anti-Tumor Treatments for Adults With Advanced Solid Tumors
Study Evaluating Safety and Effects of MK-1045 Immunotherapy in People with Follicular and Diffuse Large B-Cell Non-Hodgkin Lymphoma
Phase I Trial Evaluating Safety and Dose of PA5 Intravenous Treatment for Adults With Advanced Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Ajjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer...
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Funda Meric-Bernstam, Michael Rothe, Pam K Mangat...
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Tareq Al Baghdadi, Elizabeth Garrett-Mayer, Susan Halabi...